Abstracts tagged "race/ethnicity"

Abstract Number: 1726 • ACR Convergence 2021
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Catherine Sims¹, Amanda Eudy¹, Jayanth Doss¹, Lisa Criscione-Schreiber², Kai Sun², Rebecca Sadun¹, Jennifer Rogers² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
Abstract Number: 0601 • ACR Convergence 2021
Racial Differences in Medication Beliefs Among SLE Patients
D Ryan Anderson¹, Amanda Eudy², Megan Clowse³, Rebecca Sadun², Jennifer Rogers², Lisa Criscione-Schreiber⁴, Jayanth Doss², Corrine Volis⁵, Theresa Coles² and Kai Sun², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Chapel Hill, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Medication adherence is essential to establishing and maintaining disease remission among SLE patients. Patients’ beliefs about treatment influence engagement and adherence to therapy. We…
Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Saira Sheikh¹, Maria Naylor², Becky Lane², Jennifer Sacks², Janine Gaiha-Rohrbach² and Cherie Butts², ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Biogen, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Jacqueline O’Brien¹, Sang Hee Park², Taylor Blachley¹, Maya Marchese¹, Nicole Middaugh¹, Xue Han², Keith Wittstock² and Leslie Harrold¹, ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
Abstract Number: 1780 • ACR Convergence 2021
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Sabahath Jaleel¹, Yael Ross¹ and Marina Magrey², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Austin Wheeler¹, Gail Kerr², Ilona Jileaeva³, Asha Krishna⁴, Bryant England¹, Harlan Sayles¹, Geoffrey Thiele¹, Jill Poole¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Washington DC VA Medical Center, Washington, DC, ³Howard University Hospital, Washington, DC, ⁴Washington, D.C. VAMC, Washington, DC
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
Abstract Number: 0242 • ACR Convergence 2020
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
Majed Albirdisi¹, David d'Cruz², Shirish Sangle² and Natasha Jordan³, ¹King Fahad Medical City, riyadh, Saudi Arabia, ²guys and st thomas hospital, london, United Kingdom, ³addebrooke's hospital, cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
Abstract Number: 1258 • ACR Convergence 2020
Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Medical Institution, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: African-Americans have a higher incidence/prevalence of SLE, more lupus nephritis, higher rates of end stage renal disease and higher mortality than Caucasians. The aim…
Abstract Number: 0245 • ACR Convergence 2020
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
April Barnado¹, Robert Carroll¹ and Lee Wheless¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with patients often presenting with non-specific symptoms that can cause delays in diagnosis. Phenotype risk scores…
Abstract Number: 1291 • ACR Convergence 2020
Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity
Sara Kellahan¹, Xinliang Huang¹, Daphne Lew², Hong Xian³, Seth Eisen¹ and Alfred Kim⁴, ¹Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ²Division of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: Depression is a prevalent (24-30%) and significant comorbidity in patients with systemic lupus erythematosus (SLE) (1). As the American College of Rheumatology (ACR) classifies…
Abstract Number: 0250 • ACR Convergence 2020
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Andrea Fava¹, Jessica Li¹, Philip Carlucci², David Wofsy³, Judith James⁴, Chaim Putterman⁵, Betty Diamond⁶, Derek Fine⁷, Jose Monroy-Trujillo⁷, Kristin Haag⁷, Kristina Deonaraine⁸, The Accelerating Medicines Partnership in SLE Network⁹, William Apruzzese¹⁰, Jill Buyon¹¹ and Michelle Petri¹², ¹Johns Hopkins University, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Northwell Health, Manhasset, NY, ⁷Johns Hopkins University, Baltimore, ⁸New York University School of Medicine, New York, ⁹Multiple Institutions, Multiple Cities, ¹⁰., Boston, ¹¹Department of Medicine, NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
Abstract Number: 1398 • ACR Convergence 2020
The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
Sabrina Elliott¹, Duncan Moore² and Virginia Steen², ¹MedStar Georgetown Hospital, Alexandria, VA, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) patients with an isolated nucleolar patterned ANA (NUC ANA) make up about 15% of the SSc population, although the specific nucleolar…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 1474 • ACR Convergence 2020
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: The classic bimodal pattern of morbidity/mortality in SLE highlighted that cardiovascular events occurred later in the natural history of SLE (Urowitz & Gladman. J…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.